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A B S T R A C T
The modiﬁed Atkins diet (MAD) consists of a nearly balanced diet without any age-dependent restriction
of recommended daily calorie intake. Recently, there has been a marked increase in the use of the MAD in
the treatment of epilepsy. Over the last 8 years, evidence suggesting that the MAD may exhibit similar
anticonvulsant properties as the traditional ketogenic diet (KD) has been accumulating. KD is now an
‘evidence-based’ treatment for refractory epilepsy. Although there are currently no direct comparisons
data from the literature suggest that the KD is more efﬁcacious than the MAD. However, the MAD is
easier to administer and has better tolerability. This review discusses when to consider each diet. The
MAD may be the ﬁrst diet of choice. In case of insufﬁcient efﬁcacy under the MAD, a switch from the MAD
to the KD should be considered.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eizThe modiﬁed Atkins diet (MAD) consists of a nearly balanced
diet (60% fat, 30% protein, and 10% carbohydrates by weight),
without any restriction on the recommended daily calories
according to patient age. In 2003, this less restrictive form of
the ketogenic diet (KD) was ﬁrst reported to potentially be an
effective treatment for children and adults with epilepsy.1 Over the
last nine years, accumulating evidence has suggested that the MAD
may be as efﬁcacious as the traditional KD. Today, the MAD is no
longer considered to be a new treatment.
The KD is now a proven, ‘evidence-based’ treatment of
refractory epilepsy.2 The classical KD is based on a ratio of fat to
carbohydrate and protein, usually 3:1 or 4:1. Fat is provided as
long-chain triglycerides. Protein intake is restricted to the
minimum requirements for growth, and carbohydrate sources
are mostly limited to small portions of vegetables or fruit. The
efﬁcacy of the KD has been proven by several multicentre trials and
one randomised trial;2–5 40–50% of children on the KD experience
a 50% or greater reduction in seizure frequency. Moreover, the KD
seems to be a particularly effective treatment of some epileptic
syndromes, such as infantile spasms, Lennox–Gastaut syndrome
and myoclonic–astatic epilepsy.4,6–8
The MAD was originally designed and investigated at Johns
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doi:10.1016/j.seizure.2012.02.005restrictive dietary treatment that would be more palatable to
children and adolescents with behavioural difﬁculties whose
parents and neurologists were reluctant to start on the traditional
KD.9 The diet is ‘‘modiﬁed’’ from the classical Atkins diet in three
ways: the ‘‘induction phase’’ of the diet, during which carbohy-
drates are limited, is maintained indeﬁnitely; fat is encouraged
(not just allowed); and weight loss is not the goal (unless
nutritionally indicated).
The purpose of this review is to summarise available data on the
MAD efﬁcacy (PubMed Search from January 2000 to June 2011;
MeSH: ‘‘Epilepsy AND Atkins Diet’’) and then to discuss recent data
that may suggest a new step in dietary treatments of epilepsy.
1. Available data on the MAD: an effective dietary treatment of
refractory epilepsy
More than 10 studies including children or adults have
investigated the effectiveness of the MAD as a dietary treatment
of refractory epilepsy.10–19 Many of these studies have been
conducted prospectively. I summarised the data from these studies
in Table 1 (studies conducted in children) and Table 2 (studies
conducted in adults). These studies include about 160 patients
with refractory epilepsy who were put on the MAD. Considering
the epilepsy syndrome of the patients treated with the MAD, it is
very unlikely that the high level of efﬁcacy of the diet, as assessed
by a reduction in seizure frequency, can be explained by a GLUT 1
deﬁciency. After three months on the diet, 48% of patients (73/152)
experienced greater than a 50% reduction in seizure frequency.vier Ltd. All rights reserved.
Table 1
Data from the published studies on Atkins diet in children. The responder rate (>50% seizure reduction) is reported when available. We also determine the total of responders
from the available study at 1 month, 3 month and 6 months under modiﬁed Atkins diet.
n 1 month 3 month 6 month
Kossoff et al.13 Propective/children 20 14/20 13/20 13/20
Kang et al.11 Prospective/children 14 8/14 7/14 5/14
Porta et al.14 Retrospective/children 10 5/10 2/10 NA
Weber et al.15 Prospective/children 15 NA 6/15 NA
Miranda et al.16 Prospective/children 33 NA 17/33 13/33
Groomes et al.19 Retrospective/children 13 10/13 12/13 NA
Absence epilepsy
Total 105 37/57 (65%) 57/105 (54%) 31/67 (46%)
NA, not available.
Table 2
Data from the published studies on Atkins diet in adults. The responder rate (>50% seizure reduction) is reported when available. We also determine the total of responders
from the available study at 1 month, 3 month and 6 months under modiﬁed Atkins diet.
n 1 month 3 month 6 month
Kossoff et al.9 Prospective/adults 30 14/30 14/30 10/30
Carrette et al.10 Prospective/adults 8 NA NA 1/8
Smith et al.17 Prospective/adults 18 NA 2/17 4/14
Total 56 14/30 (47%) 16/47 (34%) 15/52 (29%)
NA, not available.
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(46/119) experiencing a similar reduction in seizure frequency.10–
17,19 About 80% (119/148) of the patients remain on the MAD for 6
months (Tables 1 and 2). These studies suggest that the MAD is an
effective treatment for refractory epilepsy. Most of the authors
reported a high degree of acceptance among patients that can be
related to the less restrictive dietary rules. Examining the available
data, the efﬁcacy of MAD might appear to be higher in children
than in adults. However, the numbers of children and adults
included in these studies are quite different. Conclusions on the
relationship between efﬁcacy and age cannot be drawn because of
the varying methods used.
2. Side effects in MAD
It has been suggested that the risk of growth impairment,
kidney stones and dyslipidaemia might be lower on the MAD than
on the KD since the MAD allows for increased protein consumption
and decreased fat intake. However, no study is available to conﬁrm
this hypothesis. The published literature has left the long-term side
effects of the MAD relatively unexplored. Some ‘side’ effects might
be considered beneﬁcial. Weight loss can occur in children and
adults who are overweight. Other beneﬁcial effects have also been
reported, such as ‘‘improved concentration, well-being and
ﬁtness,’’ ‘‘more erect posture,’’ ‘‘more ﬂuent speech,’’ and improved
mood.10
The most common side effects of the MAD are gastrointestinal
complaints and unfavourable lipid proﬁles. In the published
studies, 4 of 92 patients discontinued the MAD because of side
effects (n = 1 vomiting, n = 1 headaches), and 8/92 discontinued
the MAD because of intolerance.10–12,15,17,18 Kossoff et al. reported
that most adults did not have to discontinue MAD because of
abnormal laboratory results.12 Moreover, Kang et al. reported only
transient hyperlipidaemia.11 In a large study, slight fatigue was
observed in one-third of the patients.16 I found four studies that
detailed the incidence of MAD side effects.10,11,15,17 Regarding
gastrointestinal side effects, nausea occurred in 2/21 patients;
diarrhoea, 3/21; and constipation, 6/21.10,15 Three out of seven
patients reported feeling weak. Kang et al. reported gastrointesti-
nal disturbances in six of 14 patients (vague abdominal pain,
constipation, vomiting and diarrhoea); they did not provide moredetails. Smith et al. stated that none of their patients discontinued
the diet because of side effects or abnormal laboratory results; they
also did not observe patients with constipation.17
3. Does MAD have the same efﬁcacy than KD?
A recent prospective study conducted in Denmark suggested
that the efﬁcacy of the MAD is similar to that of the KD.16 Thirty-
three children with medically resistant epilepsy who were placed
on the MAD were included. Three months after the start of the diet,
17/33 patients (52%) experienced a reduction in seizures of at least
50%. Out of these patients, 14 patients (42%) reported seizure
reductions of greater than 90% after 3 months on the diet. In
addition, 17 patients (52%) remained on the MAD for at least 12
months. Nine of seventeen patients (27% of the 33 included
patients) experienced greater than 50% seizure reduction. To
evaluate the efﬁcacy of the MAD compared with the KD, the
authors compared their data to a previous study conducted at the
same centre.20 The percentage of responders (patients who
experienced >50% seizure reduction) after 6 months on the
MAD were compared with the percentage of responders previously
treated by the KD.16 The authors did not observe any signiﬁcant
difference between the treatment groups. A strong trend for a
higher percentage of responders was observed in the KD group
(MAD 39% vs. KD 60%, p = 0.06). However, the patients in the KD
group were signiﬁcantly younger than the patients in the MAD
group. When the authors adjusted the 2 groups for the difference in
age, this trend disappeared.16
Recently, a study aimed to determine whether switching from
the MAD to the KD would improve seizure control. The effect of the
MAD was retrospectively studied in 27 patients.21 During
treatment with the MAD, 19 subjects (70%) experienced at least
a 50% reduction in seizures, and 5 children in this study
demonstrated no improvement. After switching to the KD, the
responder rate remained stable (19 patients (70%)); however, 10
patients (37%) experienced a 10% greater seizure reduction while
on the KD than while on the MAD, and 5 children became seizure-
free. The major ﬁnding of this study was that only children who
experienced a reduction in seizures while on the MAD subse-
quently improved after switching to the KD. The KD may slightly
improve seizure control in approximately one-third of children
Table 3
Proposal on the use of modiﬁed Atkins diet (MAD) and ketogenic diet (KD)in various
epilepsy syndromes based on the beneﬁt-risk ratio.
In case of dietary treatment, the use of KD may be switched to MAD after
proved efﬁcacy
Infantile spasms – West syndrome
Myoclonic astatic epilepsy
Worsening epilepsy (any epilepsy syndrome)
Status epilepticus
In case of dietary treatment, the use of MAD may be switched to KD to
improve efﬁcacy
Absence epilepsy
GLUT-1 deﬁciency
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improvement while on the MAD improved while on the KD. This
ﬁnding suggests that these diets are probably a unique therapy in
which KD is more effective. Note that of the patients who became
seizure free, all had myoclonic–astatic epilepsy.
In conclusion, the MAD may be slightly less efﬁcacious
compared with the KD. Only a randomised trial comparing the
MAD and KD would deﬁnitively answer this question. However,
the results of the Kossof et al. study on the switch from MAD to KD
strongly support the idea that KD could be more efﬁcient,
effectively representing a ‘‘higher dose’’ of dietary treatment.21
4. When dietary treatment of epilepsy is considered, should we
use MAD or KD ﬁrst? (Table 3)
When a dietary treatment is discussed for a patient with
epilepsy, I suggest that treatment should be selected like an
antiepileptic drug (AED) is selected. The choice of an AED is based
on the balance between beneﬁts and risks, the spectrum of efﬁcacy
for the epileptic syndrome, the tolerability and its pharmacologic
properties.
In the case of a recent diagnosis of epileptic encephalopathies,
the choice should be based mostly on the efﬁcacy of the diet to
control seizure (e.g., infantile spasms). The KD should then be
considered. If the dietary treatment is considered to be an
emergency rescue treatment as in status epilepticus (SE), we also
recommend the KD. Accumulating data suggest the efﬁcacy of the
KD in the case of refractory SE.22–24 It would be possible to switch
to the MAD after the KD has provided partial or total seizure
control. The switch from one diet to the other has been reported in
a few cases without increasing the seizure frequency.14
If the KD or MAD results in full seizure control, I recommend
that the possibility of GLUT-1 deﬁciency be investigated. Recent
data suggest that GLUT-1 deﬁciency may be the underlying cause
of myoclonic–astatic epilepsy in 5% of patients,25 and the KD has
been observed to be a particularly effective treatment of
myoclonic–astatic epilepsy.7,21 Moreover, accumulating data
suggest that GLUT-1 deﬁciency could be observed in a wide
clinical spectrum.26–31 A diagnosis of GLUT-1 deﬁciency would not
exclude the use of the MAD. In these patients, the switch from KD
to MAD should be carefully managed because little data are
available.32
If a dietary treatment is considered for a patient with epilepsy
that does not require rapid seizure control or a patient with
epileptic encephalopathy at a chronic phase, I propose to start the
MAD, which is effective but better tolerated. Patients who
experience limited MAD efﬁcacy should be switched to the KD
since an additional improvement may be observed.21 The use of a
‘Ketocomplement’ can also be considered to improve MAD
efﬁcacy.33 In a study involving 30 children with intractable
epilepsy, the MAD was initiated in combination with a daily 400-
calorie KetoCal1 shake. This diet was more effective than the usualMAD,33 and this combination may also be considered in case of
insufﬁcient seizure control on the usual MAD.
Most of the studies investigating the use of dietary treatments
of speciﬁc epilepsy syndrome have been conducted with KD;
however, now, there are a few reports on the effect of the MAD in
deﬁned epilepsy syndromes. One study investigated MAD efﬁcacy
for the treatment of absence epilepsies in 21 patients (9 KD and 12
MAD); 18 patients (82%) experienced >50% seizure reduction. Of
these 18 patients, 10 patients (48%) experienced a >90% seizure
reduction, and 4 patients (19%) were seizure free. Nine of 12
patients treated by the MAD exhibited a seizure improvement
(>50%).19 The successful use of the MAD has also been reported in
two children with non-convulsive status epilepticus.34
5. Lessons from studies on the MAD regarding the mechanisms
of action of dietary treatment
Examining the data from the studies on the MAD, it is possible
to discuss the mechanisms underlying the dietary treatment of
epilepsy (KD and/or MAD). In the study conducted by Kang et al.,
the children who experienced a greater reduction in seizures
exhibited fewer ﬂuctuations in serum ketosis.11 Limited data are
available regarding the value of serum b-hydroxybutyrate (B-OH),
but one study suggested that serum B-OH may correlate with
seizure control.35
An interesting ﬁnding of the ﬁrst paediatric study on the MAD
was that a stable body mass index (BMI) (changing less than 0.3
over the 6-month study period) correlates with seizure reduction
whereas weight loss did not.13 Experimental data have suggested
that caloric restriction exhibits anticonvulsant properties.36,37
However, it is currently impossible to clearly determine the role of
caloric restriction in the KD or MAD.
More recently, a clinical study conducted at JHH also suggested
that the amount of lipids allowed may play a role in the
anticonvulsant properties of the KD and MAD. Thirty children
with intractable epilepsy were prospectively started on the MAD in
combination with a daily 400-calorie KetoCal1 shake.33 At 1
month, 24 (80%) children experienced >50% seizure reduction, of
which 11 children (37%) experienced >90% seizure reduction. A
true control group was not used in their study; however, the
authors compared their data with published reports investigating
the use of the modiﬁed Atkins diet. They found a higher number of
responders (>50% seizure reduction) in their patients than in the
patients from these studies (37 of 64, 58%, p = .03). The authors
have hypothesised that KetoCal1 would improve ketosis. Howev-
er, they did not ﬁnd any clear increase of ketosis in their patients
compared with patients on the usual modiﬁed Atkins diet. The
daily fat intake was deﬁnitively higher in their patients suggesting
a critical role of fatty acids in the mechanism of action of dietary
therapies. In these patients, caloric intake was also increased,
suggesting that caloric restriction, theorised by some as a
mechanism of action for dietary treatments, did not appear to
be important.33 Experimental data have also shown that fatty
acids, in particular polyunsaturated fatty acids, exhibit anticon-
vulsant properties.38
The hypothesis that the KD and MAD may act or share similar
underlying mechanisms need to be further studied.
6. Conclusion
Currently, we have sufﬁcient data to state that MAD is an
efﬁcacious dietary treatment of epilepsy. Existing data are not
sufﬁcient to draw conclusions about MAD efﬁcacy relative to KD
efﬁcacy. It is currently difﬁcult to conclude that the efﬁcacy of the
MAD is similar to that of the KD. A controlled trial is needed.
However, MAD can be used as a ﬁrst dietary treatment because it
S. Auvin / Seizure 21 (2012) 237–240240has a favourable risk-beneﬁt ratio. The MAD is more palatable and
less restrictive than the KD. It is important to remember that the
KD has been shown to further improve patients who responded to
the MAD. The KD should be considered instead of the MAD in some
epilepsy syndromes when rapid improvement is required, in
particular when this may affect the outcome or in some epileptic
encephalopathies where KD is particularly effective.
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